The latest news and developments related to extracorporeal CO2 removal and the Hemolung RAS.
Intubation and mechanical ventilation are the standard method of support for patients suffering from acute respiratory failure. However, the complications associated with intubation and mechanical ventilation are significant and potentially life-threatening. These risks are often not accounted for when considering the risk to benefit profile of using low-flow, partial ECCO2R in COPD patients experiencing an acute exacerbation who are failing support with noninvasive ventilation. The complications and invasiveness of partial ECCO2R and mechanical ventilation are reviewed and compared through an extensive literature review summarized in a new white paper from ALung’s scientific staff.
The case report of a patient with severe COPD awaiting lung transplantation, who was hospitalized and intubated following at-home cardiac arrest, was recently published in the March, 2014 issue of Anaesthesia and Intensive Care. In this report, Dr. Ravi Tiruvoipati (Melbourne, Australia) describes the use of the Hemolung RAS to provide supplemental CO2 removal when the patient became severely hypercapnic with worsening respiratory acidosis while on mechanical ventilation.
We are honored to have the Hemolung RAS recognized as a finalist for the 2014 MDEA Awards. This admission is the result of more than 10 years of dedication and perseverance on the part of our staff, investors, and clinical collaborators who all share a common vision: A better future for patients suffering from acute respiratory failure.
ECCO2R at EURO-ELSO
There will be numerous presentations on ECCO2R at next month’s EURO-ELSO meeting in Paris. Sessions on ECCO2R will take place on Friday, May 23rd from 11:00–12:45 and from 13:00–14:00.
We invite you to learn more about ECCO2R with the Hemolung RAS at our booth (2) in the main exhibit hall.